2022
Navigating barriers to affording and obtaining insulin and diabetes supplies
Wilcox A, Lipska K, Weinzimer S, Gujral J, Arakaki A, Kerandi L, Nally L. Navigating barriers to affording and obtaining insulin and diabetes supplies. Journal Of Diabetes 2022, 15: 71-75. PMID: 36562281, PMCID: PMC9870729, DOI: 10.1111/1753-0407.13344.Peer-Reviewed Original ResearchFeasibility and Preliminary Safety of Smartphone-Based Automated Insulin Delivery in Adolescents and Children With Type 1 Diabetes
Deshpande S, Weinzimer SA, Gibbons K, Nally LM, Weyman K, Carria L, Zgorski M, Laffel LM, Doyle FJ, Dassau E. Feasibility and Preliminary Safety of Smartphone-Based Automated Insulin Delivery in Adolescents and Children With Type 1 Diabetes. Journal Of Diabetes Science And Technology 2022, 18: 363-371. PMID: 35971681, PMCID: PMC10973844, DOI: 10.1177/19322968221116384.Peer-Reviewed Original ResearchType 1 diabetesUnannounced exercisePercent timeGlucose standard deviationParents/guardiansSecondary outcomesAdverse eventsPrimary outcomeBlood glucose dataPump therapyPreliminary safetyAutomated Insulin DeliveryContinuous glucose monitoring dataPediatric participantsGlucose monitoring dataAge-based cohortsArtificial pancreas systemsLarge mealsInsulin deliveryGlucose dataYoung childrenDiabetesYounger cohortsChildrenCohort1025-P: Racial Disparities in Diabetes Distress and Technology Use in Adolescents with Type 1 Diabetes
WILCOX A, MENCHER S, NALLY L, WEINZIMER S. 1025-P: Racial Disparities in Diabetes Distress and Technology Use in Adolescents with Type 1 Diabetes. Diabetes 2022, 71 DOI: 10.2337/db22-1025-p.Peer-Reviewed Original ResearchNon-Hispanic whitesDiabetes distressAdverse short-term outcomesBurden of diabetesShort-term outcomesType 1 diabetesHigher HbA1cContinuous glucose monitorElevated hemoglobinHigh prevalenceHigh riskDiabetesREM groupEthnic groupsEthnic disparitiesInsulin pumpAdolescent SurveyType 1Group of adolescentsRacial disparitiesSpeakers bureauDiabetes technologyNovo NordiskGlucose monitorAdditional mediators
2021
The Influence of Health Mindset on Perceptions of Illness and Behaviors Among Adolescents
John-Henderson NA, Wright RC, Manke KJ, Fotuhi O, Zuckerman B, Nally L, Mueller CM. The Influence of Health Mindset on Perceptions of Illness and Behaviors Among Adolescents. International Journal Of Behavioral Medicine 2021, 28: 727-736. PMID: 33721232, DOI: 10.1007/s12529-021-09972-2.Peer-Reviewed Original ResearchConceptsHealthy adolescentsHealth behaviorsHealth mindsetsType 1 diabetesImplications of illnessPerception of illnessMethodsIn study 1Chronic conditionsAdditional diseaseJudgments of illnessChronic illnessHealth perceptionOverall healthIllnessGlucose monitoringAdolescentsGreater frequencyYoung adolescentsStudy 2Study 1DiabetesInjuryDiseaseAdjunctive Therapies for Type 1 Diabetes
Nally L, Van Name M, Tamborlane W, Sherr J. Adjunctive Therapies for Type 1 Diabetes. Contemporary Endocrinology 2021, 143-150. DOI: 10.1007/978-3-030-64133-7_13.Chapters
2019
Wilderness Medical Society Clinical Practice Guidelines for Diabetes Management
VanBaak KD, Nally LM, Finigan RT, Jurkiewicz CL, Burnier AM, Conrad BP, Khodaee M, Lipman GS. Wilderness Medical Society Clinical Practice Guidelines for Diabetes Management. Wilderness And Environmental Medicine 2019, 30: s121-s140. PMID: 31753543, PMCID: PMC7510348, DOI: 10.1016/j.wem.2019.10.003.Peer-Reviewed Original ResearchConceptsEvidence-based guidelinesWilderness Medical Society Clinical Practice GuidelinesUrgent therapeutic managementTreatment of complicationsClinical practice guidelinesWilderness Medical SocietyGlycemic complicationsTherapeutic managementPractice guidelinesDiabetes managementBest practice recommendationsType 1DiabetesPractice recommendationsExpert panelPreventive measuresMedical societiesComplicationsTreatmentGuidelinesPathophysiologyRecommendationsPreventionPharmacologic treatment options for type 1 diabetes: what’s new?
Nally LM, Sherr JL, Van Name MA, Patel AD, Tamborlane WV. Pharmacologic treatment options for type 1 diabetes: what’s new? Expert Review Of Clinical Pharmacology 2019, 12: 471-479. PMID: 30892094, PMCID: PMC6488361, DOI: 10.1080/17512433.2019.1597705.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsAdjunctive therapyType 1 diabetesInsulin analoguesMimic physiologic insulin secretionGLP-1 receptor agonistsPhysiologic insulin secretionPharmacologic treatment optionsDPP-4 inhibitorsType 2 diabetesVariety of insulinBiosynthetic human insulinPotential adverse effectsSGLT1/2 inhibitorsBasal insulinPharmacologic treatmentTreatment optionsReceptor agonistInsulin secretionSGLT-2Abnormal physiologyProlonged durationTherapyDiabetesInsulinNovel drugs